Monosodium Risedronate Hemipentahydrate is primarily used in the treatment of bone-related disorders. It is effective in managing osteoporosis by increasing bone density and reducing the risk of fractures. This compound is also utilized in treating Paget's disease, a condition characterized by abnormal bone remodeling. Additionally, it aids in preventing bone loss in patients undergoing certain medical treatments, such as long-term corticosteroid therapy. Its mechanism involves inhibiting osteoclast-mediated bone resorption, thereby promoting bone strength and stability.